TRISTEL plc

("Tristel" or the "Company")

Publication of Poster by Mayo Clinic

North America update

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, notes the publication of a poster by the Mayo Clinic at the AORN* Global Surgical Conference & Expo in Boston, MA (USA) published this week, entitled, "Implementing a new method of High-Level disinfection foam for ultrasound probes."

The poster reported on the outcome of a new method of High-Level Disinfection ("HLD"), Tristel ULT™, used in a 90-day trial by 11 Mayo Clinic staff members to reprocess 189 ultrasound probes, with no reported surgical site infections during the trial.

The poster described the new method of HLD foam as an effective and efficient method for HLD of ultrasound probes with minimal reprocessing turn-around time as well as being safe, easy to use, and cost effective. The poster also describes how the new HLD foam reduces reprocessing time minimising the number of ultrasound probes needed as well as reducing the damage to ultrasound probes compared to other methods.

The full poster can be viewed here: https://investors.tristel.com/wp-content/uploads/2025/04/AORN-Poster-Mayo-Clinic.pdf

This positive case-study of US adoption follows the news announced in February 2025 that an updated standard compiled by the Association for the Advancement of Medical Instrumentation (AAMI) and adopted by the American National Standards Institute (ANSI) acknowledged chlorine dioxide foam as a novel modality for high-level disinfection of medical devices.

This also adds to the growing number of US case studies that highlight Tristel ULT™ as a novel HLD able to achieve faster, simpler endocavitary probe processing for busy urology practices. In May 2024, US urologist, Dr Matthew Allaway, published a white paper called "Simplifying High-Level Disinfection for Urological Procedures: A Case Study" https://www.parkerlabs.com/wp-content/uploads/2024/04/AllawayWhitePaper_8_LOCKED.pdf

North America update

Sales of Tristel ULT in North America continue to build momentum, with strong sequential growth delivered quarter on quarter in line with internal forecasts.

The solid growth reflects increasing adoption of the Company's technology, supported by growing customer engagement and expanding usage within existing accounts. At the end of the third quarter, so far this financial year the Company estimates that Tristel ULT had been used for over 200,000 disinfection procedures in North America.

Matt Sassone, Chief Executive Officer of Tristel, commented: "We are delighted to see such positive feedback on the use of Tristel ULT in clinical practice at the renowned Mayo Clinic. As a leading US hospital, the Mayo Clinic pride themselves in excellence and are always seeking to adopt the best possible practices in infection control. To have them present this poster to the thousands of perioperative professionals who attend this conference is a great support to our plans to wider drive adoption in the US. 

"We're confident in our continued momentum across North America and we look forward to US revenues becoming substantial in the years ahead. As Tristel ULT is manufactured in the United States by our partner, Parker Labs, we're confident that the newly announced tariffs will have no adverse impact on our pricing or sales performance in North America."

Notes

*Association of periOperative Registered Nurses

For further information please contact:

About Tristel plc

Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO₂) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals under the Tristel brand, and under the Cache brand provides products for sporicidal surface disinfection, a more sustainable alternative to commonly used pre-wetted plastic wipes.

Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 270 people across 16 subsidiaries selling into 40+ countries. The Company targets annual revenue growth of between 10% and 15% and an EBITDA margin of at least 25% and the business is profitable, with no debt and has a progressive dividend policy.

The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).

For more information about Tristel's product range please visit: https://tristel.com